Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to gamma-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“irradiation can also increase tumor antigenicity through enriching the pool of antigenic peptides”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reits et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“folding the HLA-A1 heavy chain with peptides CGI-51(206–215), MSH6(469–478), and F-box protein Fbl7(335–362) and human β2m as described (51).”
BackgroundDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
Schubert, U., Antón, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., & Bennink, J. R. (2000) · Nature · doi:10.1038/35008096 · Cited by 1,536
Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags
Mann, M., & Wilm, M. (1994) · Analytical Chemistry · doi:10.1021/ac00096a002 · Cited by 1,468
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 3×
“This is probably not due only to up-regulation of MHC class I expression because mTOR activation will have more general eff ects on protein expression including up-regulation of Fas, ICAM-1 (38), and interferon expression (33, 34).”
Background
Research works printed but not linked: 5
- 2000, Oncology (Huntingt), 14, 741
- 1988, Nippon Igaku Hoshasen Gakkai Zasshi., 48, 1572
- 2000, Anticancer Res., 20, 3375
- 2002, Cancer Res., 62, 1462
- 1991, Cancer Res., 51, 3657
Cited by
Items 201–300 of 1,000
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma
Maggs, L., Cattaneo, G., Dal, A. E., Moghaddam, A. S., & Ferrone, S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.662064 · Cited by 159
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A., Wang, T. W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214788 · Cited by 152
Tai, D. W.-M., Loke, K. S. H., Gogna, A., Kaya, N. A., Tan, S. H., Hennedige, T. P., Ng, D. C., Irani, F. G., Lee, J. J. X., Lim, J. Q., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00305-8 · Cited by 158
Relative Expression Levels of the HLA Class-I Proteins in Normal and HIV-Infected Cells
Apps, R., Meng, Z., Prete, G. Q. D., Lifson, J. D., Zhou, M., & Carrington, M. N. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403234 · Cited by 156
Pateras, I. S., Havaki, S., Nikitopoulou, X., Vougas, K. N., Townsend, P. A., Panayiotidis, M. I., Georgakilas, A. G., & Gorgoulis, V. G. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.011 · Cited by 156
Hodge, J. W., Ardiani, A., Farsaci, B., Kwilas, A. R., & Gameiro, S. R. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.006 · Cited by 155
Self-citationRadiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment
Zhu, S., Wang, Y., Tang, J., & Cao, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074477 · Cited by 155
Wang, L., Lynch, C. M., Pitroda, S. P., Piffkó, A., Yang, K., Huser, A. K., Liang, H. L., & Weichselbaum, R. R. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232101 · Cited by 155
Sebastian, M., Papachristofilou, A., Weiss, C., Früh, M., Cathomas, R., Hilbe, W., Wehler, T., Rippin, G., Koch, S. D., Scheel, B., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-748 · Cited by 141
Dovedi, S. J., Melis, M. H. M., Wilkinson, R. W., Adlard, A. L., Stratford, I. J., Honeychurch, J., & Illidge, T. (2012) · Blood · doi:10.1182/blood-2012-05-432393 · Cited by 154
The Promise of Combining Radiation Therapy With Immunotherapy
Jagodinsky, J. C., Harari, P. M., & Morris, Z. S. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.04.023 · Cited by 154
Treatment advances across the cervical cancer spectrum
Francoeur, A., Monk, B. J., & Tewari, K. S. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00977-w · Cited by 154
Frey, B., Rubner, Y., Wunderlich, R., Weiss, E., Pockley, A. G., Fietkau, R., & Gaipl, U. S. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800099811 · Cited by 154
Harnessing the immune system to treat cancer
Bhardwaj, N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32136 · Cited by 152
Madan, R. A., Gulley, J. L., Schlom, J., Steinberg, S. M., Liewehr, D. J., Dahut, W. L., & Arlen, P. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5048 · Cited by 150
Self-citationLussier, D. M., Alspach, E., Ward, J. P., Miceli, A. P., Runci, D., White, J. M., Mpoy, C., Arthur, C. D., Kohlmiller, H. N., Jacks, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102611118 · Cited by 152
Kordbacheh, T., Honeychurch, J., Blackhall, F. H., Finn, C. F., & Illidge, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx790 · Cited by 152
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
Spain, L. A., Higgins, R. M., Gopalakrishnan, K., Turajlic, S., Gore, M. E., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw130 · Cited by 150
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 151
Combination of Radiotherapy and Immune Checkpoint Inhibitors
Pilones, K. A., Vanpouille‐Box, C., & Demaria, S. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.004 · Cited by 151
The abscopal effect 67 years later: from a side story to center stage
Demaria, S., & Formenti, S. C. (2020) · British Journal of Radiology · doi:10.1259/bjr.20200042 · Cited by 149
Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors
Antón, L. C., & Yewdell, J. W. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.1113599 · Cited by 148
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 139
Current status of immune checkpoint inhibition in early-stage NSCLC
Vansteenkiste, J., Wauters, E., Reymen, B. J. T., Ackermann, C. J., Peters, S., & Ruysscher, D. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz175 · Cited by 145
Radiotherapy and the immune system: More than just immune suppression
Rückert, M., Flohr, A.-S., Hecht, M., & Gaipl, U. S. (2021) · Stem Cells · doi:10.1002/stem.3391 · Cited by 145
Anti-HER2 vaccines: new prospects for breast cancer therapy
Ladjemi, M. Z., Jacot, W., Chardès, T., Pèlegrin, A., & Navarro‐Teulon, I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0869-2 · Cited by 145
Sharma, A., Bode, B., Wenger, R. H., Lehmann, K., Sartori, A. A., Moch, H., Knuth, A. K., von Boehmer, L., & van den Broek, M. F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028217 · Cited by 146
Menon, H., Chen, D., Ramapriyan, R., Verma, V., Barsoumian, H. B., Cushman, T. R., Younes, A. I. A., Cortez, M. A., Erasmus, J. J., de Groot, P. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0718-6 · Cited by 144
Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments
Cuzzubbo, S., Mangsbo, S. M., Nagarajan, D., Habra, K., Pockley, A. G., & McArdle, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615240 · Cited by 145
Radiation triggering immune response and inflammation
Hekim, N., Çetin, Z., Nikitaki, Z., Çört, A., & Saygılı, E. İ. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.016 · Cited by 140
Type I IFN protects cancer cells from CD8+ T cell–mediated cytotoxicity after radiation
Chen, J., Cao, Y., Markelc, B., Kaeppler, J., Vermeer, J. A. F., & Muschel, R. J. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127458 · Cited by 128
The Tumor-Immune Microenvironment and Response to Radiation Therapy
Shiao, S. L., & Coussens, L. M. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9194-9 · Cited by 125
Lebow, E. S., Hubbeling, H., Yeap, B. Y., Mehan, W. A., Shaw, A. T., Oh, K. S., Gainor, J. F., & Shih, H. A. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.02.175 · Cited by 138
Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle
Li, Q., Shi, Z., Zhang, F., Zeng, W., Zhu, D., & Mei, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.031 · Cited by 138
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
Toll-like Receptors in Tumor Immunotherapy
Paulos, C. M., Kaiser, A., Wrzesinski, C., Hinrichs, C. S., Cassard, L., Boni, A., Muranski, P. J., Sanchez-Perez, L. A., Palmer, D. C., Yu, Z., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1378 · Cited by 136
Balogh, A., Persa, E., Bogdándi, E. N., Benedek, A., Hegyesi, H., Sáfrány, G., & Lumniczky, K. (2012) · Inflammation Research · doi:10.1007/s00011-012-0567-y · Cited by 133
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 132
Immunologically augmented cancer treatment using modern radiotherapy
Durante, M., Reppingen, N., & Held, K. D. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.007 · Cited by 132
Skinner, H. D., Giri, U. P., Yang, L. P., Kumar, M., Liu, Y., Story, M. D., Pickering, C. R., Byers, L. A., Williams, M. D., Wang, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2586 · Cited by 131
Oxidative Stress in Cancer Therapy: Friend or Enemy?
Azmanova, M., & Pitto‐Barry, A. (2022) · ChemBioChem · doi:10.1002/cbic.202100641 · Cited by 131
Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer
Eckert, F., Schilbach, K., Klumpp, L., Bardoscia, L., Sezgın, E., Schwab, M. G., Zips, D., & Huber, S. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03018 · Cited by 130
Joshi, S., & Durden, D. L. (2019) · Journal of Oncology · doi:10.1155/2019/5245034 · Cited by 129
Geng, Y., Zhang, Q., Feng, S., Li, C., Wang, L., Zhao, X., Yang, Z., Li, Z., Luo, H., Liu, R., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3718 · Cited by 129
Poleszczuk, J., Luddy, K. A., Prokopiou, S., Robertson‐Tessi, M., Moros, E. G., Fishman, M., Djeu, J. Y., Finkelstein, S. E., & Enderling, H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1423 · Cited by 128
Structural and regulatory diversity shape HLA-C protein expression levels
Kaur, G., Gras, S., Mobbs, J. I., Vivian, J. P., Cortés, A., Barber, T. R., Kuttikkatte, S. B., Jensen, L. T., Attfield, K. E., Dendrou, C. A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15924 · Cited by 127
Sevenich, L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00163 · Cited by 129
Sensors of ionizing radiation effects on the immunological microenvironment of cancer
Demaria, S., & Formenti, S. C. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701481816 · Cited by 127
Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival
Poleszczuk, J., Luddy, K. A., Chen, L., Lee, J. K., Harrison, L. B., Czerniecki, B. J., Soliman, H. H., & Enderling, H. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0870-1 · Cited by 126
Targeted Therapies to Improve Tumor Immunotherapy
Begley, J. L., & Ribas, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4804 · Cited by 126
Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies
Rückert, M., Deloch, L., Fietkau, R., Frey, B., Hecht, M., & Gaipl, U. S. (2018) · Strahlentherapie und Onkologie · doi:10.1007/s00066-018-1287-1 · Cited by 125
Future of Radiotherapy in Nasopharyngeal Carcinoma
Sun, X.-S., Li, X. N., Chen, Q.-Y., Tang, L., & Mai, H. (2019) · British Journal of Radiology · doi:10.1259/bjr.20190209 · Cited by 124
Therapeutic potential of CAR T cell in malignancies: A scoping review
Mehrabadi, A. Z., Ranjbar, R., Farzanehpour, M., Shahriary, A., Dorostkar, R., Hamidinejad, M. A., & Ghaleh, H. E. G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112512 · Cited by 124
Goedegebuure, R. S. A., de Klerk, L. K., Bass, A. J., Derks, S., & Thijssen, V. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03107 · Cited by 123
The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership
Chajon, É., Castelli, J., Marsiglia, H. R., & de Crevoisier, R. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.017 · Cited by 124
PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes
Du, S., Zhou, L., Alexander, G. S., Park, K., Yang, L., Wang, N., Zaorsky, N. G., Ma, X., Wang, Y., Dicker, A. P., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.002 · Cited by 115
Marill, J., Anesary, N. M., & Paris, S. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.07.029 · Cited by 122
Key mechanisms involved in ionizing radiation-induced systemic effects. A current review
Mavragani, I. V., Laskaratou, D., Frey, B., Candéias, S. M., Gaipl, U. S., Lumniczky, K., & Georgakilas, A. G. (2015) · Toxicology Research · doi:10.1039/c5tx00222b · Cited by 123
Long, J., Lin, J., Wang, A., Wu, L., Zheng, Y., Yang, X., Wan, X., Xu, H., Chen, S., & Zhao, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0511-2 · Cited by 116
Guipaud, O., Jaillet, C., Clément-Colmou, K., François, A., Supiot, S., & Milliat, F. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170762 · Cited by 121
Krisnawan, V. E., Stanley, J. A., Schwarz, J. K., & DeNardo, D. G. (2020) · Cancers · doi:10.3390/cancers12102916 · Cited by 123
Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Yin, S., Chen, Z., Chen, D., & Yan, D. (2023) · Theranostics · doi:10.7150/thno.80091 · Cited by 121
Sethumadhavan, S., Silva, M., Philbrook, P., Nguyen, T., Hatfield, S. M., Ohta, A., & Sitkovsky, M. V. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187314 · Cited by 119
Derer, A., Deloch, L., Rubner, Y., Fietkau, R., Frey, B., & Gaipl, U. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00505 · Cited by 119
Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications
Popp, I., Grosu, A., Niedermann, G., & Duda, D. G. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.07.013 · Cited by 119
Lan, J., Li, R., Yin, L., Deng, L., Gui, J., Chen, B.-Q., Zhou, L., Meng, M., Huang, Q., Mo, X., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.01.071 · Cited by 119
Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy
Zhu, Y., Yu, X., Thamphiwatana, S., Zheng, Y., & Pang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.010 · Cited by 118
Awakening the immune system with radiation: Optimal dose and fractionation
Gandhi, S. J., Minn, A. J., Vonderheide, R. H., Wherry, E. J., Hahn, S. M., & Maity, A. M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.024 · Cited by 117
Antitumor Immunity Induced after α Irradiation
Gorin, J.-B., Ménager, J., Gouard, S., Maurel, C., Guilloux, Y., Faivre-Chauvet, A., Morgenstern, A., Bruchertseifer, F., Chérel, M., Davodeau, F., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.04.002 · Cited by 103
Combinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 117
Hodge, J. W., Guha, C., Neefjes, J., & Gulley, J. L. (2008) · PubMed · Cited by 117
Self-citationTurning Tumors into Vaccines: Co-opting the Innate Immune System
van den Boorn, J. G., & Hartmann, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.011 · Cited by 118
Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry
Freudenmann, L. K., Marcu, A., & Stevanović, S. (2018) · Immunology · doi:10.1111/imm.12936 · Cited by 109
Immuno-oncology combinations: raising the tail of the survival curve
Harris, S. J., Harris, S. J., Brown, J. S., Lopez, J. S., Yap, T. A., Brown, J. S., Lopez, J. S., & Yap, T. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0015 · Cited by 114
An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models
Markovsky, E., Budhu, S., Samstein, R. M., Li, H., Russell, J., Zhang, Z., Drill, E. N., Bodden, C., Chen, Q., Powell, S. N., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.10.009 · Cited by 114
Loenhout, J. V., Peeters, M., Bogaerts, A., Smits, E., & Deben, C. (2020) · Antioxidants · doi:10.3390/antiox9121188 · Cited by 114
Patel, R. R., He, K., Barsoumian, H. B., Chang, J. Y., Tang, C. Z., Verma, V., Comeaux, N. I., Chun, S. G., Gandhi, S. J., Truong, M. T., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.06.037 · Cited by 113
Kwilas, A. R., Donahue, R. N., Bernstein, M. B., & Hodge, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00104 · Cited by 111
Self-citationTargeting innate sensing in the tumor microenvironment to improve immunotherapy
Liu, Z., Han, C., & Fu, Y. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0341-y · Cited by 111
Fang, C., Mo, F., Liu, L., Du, J., Luo, M., Men, K., Na, F., Wang, W., Yang, H., & Wei, X. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0456-1 · Cited by 114
Beneficial autoimmunity improves cancer prognosis
Zitvogel, L., Perreault, C., Finn, O. J., & Kroemer, G. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00508-x · Cited by 112
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.008 · Cited by 106
Immunotherapy in glioblastoma treatment: Current state and future prospects
Pinheiro, S. L. R., Lemos, F. F. B., Marques, H. S., Luz, M. S., Silva, L. G. D. O., dos Santos, C. F. S. M., Evangelista, K. D. C., Calmon, M. S., Loureiro, M. S., & de Melo, F. F. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i4.138 · Cited by 111
Overview of Cellular Immunotherapy for Patients with Glioblastoma
Vauléon, É., Avril, T., Collet, B., Mosser, J., & Quillien, V. (2010) · Journal of Immunology Research · doi:10.1155/2010/689171 · Cited by 110
Maity, A. M., Mick, R., Huang, A. C. C., George, S. M., Farwell, M. D., Lukens, J. N., Berman, A. T., Mitchell, T. C., Bauml, J., Schuchter, L. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0281-9 · Cited by 110
Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development
Majc, B., Novak, M., Kopitar‐Jerala, N., Jewett, A., & Breznik, B. (2021) · Cells · doi:10.3390/cells10020265 · Cited by 110
Stopfer, L. E., Mesfin, J. M., Joughin, B. A., Lauffenburger, D. A., & White, F. M. (2020) · Nature Communications · doi:10.1038/s41467-020-16588-9 · Cited by 109
Immunogenic Apoptotic Cell Death and Anticancer Immunity
Vandenabeele, P., Vandecasteele, K., Bachert, C., Krysko, O., & Krysko, D. V. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_6 · Cited by 110
Medler, T. R., Cotechini, T., & Coussens, L. M. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.07.008 · Cited by 109
The impact of radiation therapy on the antitumor immunity: Local effects and systemic consequences
Lumniczky, K., & Sáfrány, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.024 · Cited by 109
The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses
Jongsma, M. L. M., de Waard, A. A., Raaben, M., Zhang, T., Cabukusta, B., Platzer, R., Blomen, V. A., Xagara, A., Verkerk, T., Bliss, S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2020.11.003 · Cited by 108
Self-citationLiu, C., Wang, X., Qin, W., Tu, J., Li, C., Zhao, W., Ma, L., Liu, B., Qiu, H., & Yuan, X. (2023) · 癌症:英文版 · doi:10.1002/cac2.12412 · Cited by 108
Murshid, A., Gong, J., Stevenson, M. A., & Calderwood, S. K. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.124 · Cited by 109
An Update on Immunotherapy for Solid Tumors: A Review
Pham, T. D., Roth, S., Kong, J. C. H., Guerra, G., Narasimhan, V., Pereira, L. A., Desai, J., Heriot, A. G., & Ramsay, R. G. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6658-4 · Cited by 108
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Anderson, P., Aptsiauri, N., Ruiz-Cabello, F., & Garrido, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00634-7 · Cited by 107
Immunoproteasomes at the interface of innate and adaptive immune responses: two faces of one enzyme
Krüger, E., & Kloetzel, P. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.01.005 · Cited by 107
Combining radiotherapy with immunotherapy: the past, the present and the future
Limbergen, E. J. V., Ruysscher, D. D., Pimentel, V. O., Marcus, D., Berbée, M., Hoeben, A., Rekers, N. H., Theys, J., Yaromina, A., Dubois, L. J., et al. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170157 · Cited by 107
Xie, C., Duffy, A. G., Brar, G. S., Fioravanti, S., Mabry‐Hrones, D., Walker, M., Bonilla, C. M., Wood, B. J., Citrin, D. E., Ramirez, E. M. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3624 · Cited by 107
Murty, S., Haile, S. T., Beinat, C., Aalipour, A., Alam, I. S., Murty, T., Shaffer, T. M., Patel, C. B., Graves, E. E., Mackall, C. L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1757360 · Cited by 106
Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
Khan, M. S. I., Arooj, S., & Wang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651634 · Cited by 106
Metadata
- Authors
- Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., & Neefjes, J. J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- 2Laboratory of Tumor Immunology and Biology
- National Institutes of Health (US)
- 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, and Centre for Medical Systems Biology, 2333 2A Leiden, Netherlands
- Leiden University Medical Center (NL)
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-04-24
- Volume
- 203
- Issue
- 5
- Pages
- 1259-1271
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3212727
- OpenAlex
- W2127733313
- Cited by
- 1,737
- References
- 53
- Citations by year
- 2026: 88 · 2025: 116 · 2024: 119 · 2023: 128 · 2022: 149 · 2021: 174 · 2020: 154 · 2019: 118 · 2018: 112 · 2017: 113 · 2016: 78 · 2015: 71 · 2014: 67 · 2013: 62 · 2012: 41
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- radiotherapy, gamma irradiation, MHC class I expression, antigen presentation, protein degradation, mTOR signaling, translation (biology), cytotoxic T lymphocytes, cancer immunotherapy, colon adenocarcinoma
- MeSH terms
- Adenocarcinoma, Animals, Colonic Neoplasms, Dose-Response Relationship, Radiation, Gamma Rays, Humans, Immunotherapy, Mice, Transgenic, Peptides, Protein Kinases, Radiotherapy, T-Lymphocytes, Cytotoxic, Protein Biosynthesis, HLA-A2 Antigen, Gene Expression Regulation, Neoplastic, Antigen Presentation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.